403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
DR Congo Gets First Ebola Vaccine Shipment to Contain Outbreak
(MENAFN) The Democratic Republic of Congo receives its first shipment of Ebola vaccines as authorities step up efforts to contain the ongoing outbreak, according to health officials.
A total of 16,520 doses of the Ervebo vaccine arrive in the country, while more than 50,000 additional doses are expected to be delivered by Monday, Health Minister Samuel Roger Kamba says.
“These doses would strengthen the government’s response to Ebola and contribute to the protection of populations, with the support of our partners,” Kamba told reporters in Kinshasa.
According to reports, the World Health Organization announces that 70,000 vaccine doses will be made available to Congo from the global Ebola vaccine stockpile. The supply is intended to support a Phase 3 clinical trial examining the vaccine’s potential impact on the Bundibugyo virus, while also providing protection for frontline and healthcare workers.
There is currently no approved vaccine or specific treatment targeting the Bundibugyo virus.
The Ervebo vaccine, meanwhile, is licensed and recommended for use during outbreaks caused by the Ebola virus, formerly known as Zaire ebolavirus.
The latest update from Congo’s Health Ministry puts the number of confirmed infections in the current outbreak at 5,290, with more than 2,500 people reported dead.
A total of 16,520 doses of the Ervebo vaccine arrive in the country, while more than 50,000 additional doses are expected to be delivered by Monday, Health Minister Samuel Roger Kamba says.
“These doses would strengthen the government’s response to Ebola and contribute to the protection of populations, with the support of our partners,” Kamba told reporters in Kinshasa.
According to reports, the World Health Organization announces that 70,000 vaccine doses will be made available to Congo from the global Ebola vaccine stockpile. The supply is intended to support a Phase 3 clinical trial examining the vaccine’s potential impact on the Bundibugyo virus, while also providing protection for frontline and healthcare workers.
There is currently no approved vaccine or specific treatment targeting the Bundibugyo virus.
The Ervebo vaccine, meanwhile, is licensed and recommended for use during outbreaks caused by the Ebola virus, formerly known as Zaire ebolavirus.
The latest update from Congo’s Health Ministry puts the number of confirmed infections in the current outbreak at 5,290, with more than 2,500 people reported dead.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment